Mark E Schmidt

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. pmc Profiling of hepatic clearance pathways of Pittsburgh compound B and human liver cytochrome p450 phenotyping
    Anne Van Vlaslaer
    Experimental Medicine, Janssen Research and Development, Division of Janssen Pharmaceutica, NV Turnhoutseweg 30, B 2340, Beerse, Belgium
    EJNMMI Res 3:10. 2013
  2. doi request reprint A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia
    Mark E Schmidt
    Janssen Research and Development, a division of Janssen Pharmaceutica NV, Beerse, Belgium
    Eur Neuropsychopharmacol 22:721-33. 2012
  3. doi request reprint Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects
    Mark E Schmidt
    Johnson and Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, 2340, Beerse, Belgium
    Psychopharmacology (Berl) 208:109-19. 2010
  4. doi request reprint The Alzheimer's disease neuroimaging initiative: perspectives of the Industry Scientific Advisory Board
    Mark E Schmidt
    Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium
    Alzheimers Dement 6:286-90. 2010
  5. doi request reprint Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
    Ion George Anghelescu
    Janssen Research and Development, a division of Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, QJ Belgium, Germany Electronic address
    Eur Neuropsychopharmacol 23:1043-50. 2013
  6. doi request reprint D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection
    Mark E Schmidt
    Experimental Medicine, Janssen Research and Development, Janssen Pharmaceutica NV, Beerse, Belgium
    Psychopharmacology (Berl) 224:549-57. 2012
  7. doi request reprint PET imaging shows loss of striatal PDE10A in patients with Huntington disease
    Rawaha Ahmad
    From University Hospitals Leuven R A, S B, A P, K V L, W V KU Leuven R A, A P, G B, K V L, W V and Janssen Pharmaceutica NV M E S, Beerse, Belgium
    Neurology 82:279-81. 2014

Collaborators

Detail Information

Publications7

  1. pmc Profiling of hepatic clearance pathways of Pittsburgh compound B and human liver cytochrome p450 phenotyping
    Anne Van Vlaslaer
    Experimental Medicine, Janssen Research and Development, Division of Janssen Pharmaceutica, NV Turnhoutseweg 30, B 2340, Beerse, Belgium
    EJNMMI Res 3:10. 2013
    ..Subjects enrolled in AD trials may start or stop medications that inhibit or induce xenobiotic metabolizing enzymes such as the cytochrome P450 (CYP) isozymes...
  2. doi request reprint A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia
    Mark E Schmidt
    Janssen Research and Development, a division of Janssen Pharmaceutica NV, Beerse, Belgium
    Eur Neuropsychopharmacol 22:721-33. 2012
    ..All JNJ-37822681 dose groups showed lesser weight gain compared with olanzapine. The efficacy and tolerability profile of the JNJ-37822681 10 mg bid was consistent with the study hypothesis...
  3. doi request reprint Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects
    Mark E Schmidt
    Johnson and Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, 2340, Beerse, Belgium
    Psychopharmacology (Berl) 208:109-19. 2010
    ....
  4. doi request reprint The Alzheimer's disease neuroimaging initiative: perspectives of the Industry Scientific Advisory Board
    Mark E Schmidt
    Johnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium
    Alzheimers Dement 6:286-90. 2010
    ..Although positioned as an advisory body, ISAB also actively contributes to the ADNI mission of identifying biomarkers of disease progression...
  5. doi request reprint Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?
    Ion George Anghelescu
    Janssen Research and Development, a division of Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, QJ Belgium, Germany Electronic address
    Eur Neuropsychopharmacol 23:1043-50. 2013
    ..40 in olanzapine group. Early improvement in PANSS may be a simple and reliable way to predict sustained response with JNJ-37822681 in patients with acute schizophrenia...
  6. doi request reprint D₂-receptor occupancy measurement of JNJ-37822681, a novel fast off-rate D₂-receptor antagonist, in healthy subjects using positron emission tomography: single dose versus steady state and dose selection
    Mark E Schmidt
    Experimental Medicine, Janssen Research and Development, Janssen Pharmaceutica NV, Beerse, Belgium
    Psychopharmacology (Berl) 224:549-57. 2012
    ..Receptor occupancy at steady state was explored to test the validity of the single-dose estimates during chronic treatment...
  7. doi request reprint PET imaging shows loss of striatal PDE10A in patients with Huntington disease
    Rawaha Ahmad
    From University Hospitals Leuven R A, S B, A P, K V L, W V KU Leuven R A, A P, G B, K V L, W V and Janssen Pharmaceutica NV M E S, Beerse, Belgium
    Neurology 82:279-81. 2014
    ..4) In light of these conflicting results and the strong interest in development of PDE10A inhibitors for clinical use in HD, it is important to determine whether PDE10A levels are affected in the striatum of patients with HD in vivo. ..